Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Niagen Bioscience (NAGE) over the last 14 years, with Q3 2025 value amounting to -$64.3 million.

  • Niagen Bioscience's Enterprise Value fell 9843.82% to -$64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.3 million, marking a year-over-year decrease of 9843.82%. This contributed to the annual value of -$44.7 million for FY2024, which is 6344.01% down from last year.
  • Niagen Bioscience's Enterprise Value amounted to -$64.3 million in Q3 2025, which was down 9843.82% from -$60.5 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Enterprise Value peaked at -$13.3 million during Q3 2022, and registered a low of -$64.3 million during Q3 2025.
  • In the last 5 years, Niagen Bioscience's Enterprise Value had a median value of -$27.9 million in 2024 and averaged -$33.3 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 22848.32% in 2021, then skyrocketed by 5993.6% in 2022.
  • Quarter analysis of 5 years shows Niagen Bioscience's Enterprise Value stood at -$28.2 million in 2021, then rose by 27.56% to -$20.4 million in 2022, then crashed by 33.68% to -$27.3 million in 2023, then plummeted by 63.44% to -$44.7 million in 2024, then crashed by 43.95% to -$64.3 million in 2025.
  • Its Enterprise Value stands at -$64.3 million for Q3 2025, versus -$60.5 million for Q2 2025 and -$55.6 million for Q1 2025.